Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 15 min 27 sec ago

Bioventus Announces U.S. Debut of Feature-Rich New EXOGEN(R) Device

Tue, 06/10/2014 - 15:30
DURHAM, N.C.--(Healthcare Sales & Marketing Network)--Bioventus, a global leader in active orthopaedic healing, today rolled out the next generation of its market-leading1EXOGEN® Ultrasound Bone Healing System, which includes a variety of new complianc...
Devices, Orthopaedic, Product Launch
Bioventus, EXOGEN , Ultrasound Bone Healing System

Auxogyn Receives FDA Clearance for Its Eeva(TM) System

Tue, 06/10/2014 - 14:52
Breakthrough Test Provides First-of-a-Kind Objective Assessment of Embryo Development Potential MENLO PARK, Calif.--(Healthcare Sales & Marketing Network)--Auxogyn, Inc. a leader in women’s reproductive health, today announced that its first product, th...
Devices, FDA
Auxogyn, Eeva System, in vitro fertilization

Pulsar Vascular Receives FDA IDE Approval for the PulseRider(R) Aneurysm Neck Reconstruction Device for the Treatment of Intracranial Bifurcation Aneurysms

Tue, 06/10/2014 - 14:45
SAN JOSE, Calif., June 10, 2014 -- (Healthcare Sales & Marketing Network) -- Pulsar Vascular, the innovator and developer of the PulseRider®, a minimally invasive, aneurysm neck reconstruction device, announced today the United States Food and Drug Ad...
Devices, Interventional, FDA
Pulsar Vascular, PulseRider, bifurcation, aneurysm

Cohera Medical, Inc.(R)'s TissuGlu(R) Surgical Adhesive Advances to Food and Drug Administration Advisory Panel Meeting

Tue, 06/10/2014 - 14:37
PITTSBURGH, June 10, 2014 -- (Healthcare Sales & Marketing Network) -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received notice from the U.S. Food and Drug Admi...
Devices, Surgery, FDA
Cohera Medical, TissuGlu, Surgical Adhesive

Ivera Medical Asserts New Patent Litigation Against Competitors

Tue, 06/10/2014 - 14:33
SAN DIEGO, CA--(Healthcare Sales & Marketing Network) - Ivera Medical Corporation, a certified minority-owned business, announced it has filed patent infringement lawsuits against its competitors in federal court in San Diego. U.S. Patent No. 8,740,864, is...
Devices, Litigation
Ivera Medical, Curos, Port Protector

Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study Comparing AVP-825 to Oral Sumatriptan for the Acute Treatment of Migraine

Tue, 06/10/2014 - 10:56
Migraine Sufferers Achieved Greater Rates of Pain Relief and Pain Freedom Within 30 Minutes with AVP-825 Treatment Compared with Oral Sumatriptan Treatment ALISO VIEJO, Calif., June 10, 2014 -- (Healthcare Sales & Marketing Network) -- Avanir Pharmaceu...
Avanir Pharmaceuticals, AVP-825, COMPASS study, migraine

Giovanni Caforio, M.D., Appointed Chief Operating Officer and Elected to Board of Directors

Tue, 06/10/2014 - 00:48
NEW YORK--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. H...
Biopharmaceuticals, Personnel
Bristol-Myers Squibb

Solstice Biologics Appoints Dr. Lou Tartaglia as President, Chief Executive Officer; John Borgeson Joins as Chief Financial Officer

Tue, 06/10/2014 - 00:43
Leadership team expanded following achievement of technology milestones SAN DIEGO, June 9, 2014 -- (Healthcare Sales & Marketing Network) -- Solstice Biologics LLC, a company focused on the targeting and delivery of nucleic acid therapeutics, today ann...
Biopharmaceuticals, Personnel
Solstice Biologics

Rubicon Genomics Adds European Distributors Ahead Of New Product Launches

Tue, 06/10/2014 - 00:38
Rubicon Is Expanding Worldwide Distribution Channels for Its Growing Line of DNA Library Prep Kits In Advance of Upcoming New Product Launches ANN ARBOR, Mich., June 9, 2014 -- (Healthcare Sales & Marketing Network) -- Rubicon Genomics, Inc., today ann...
Diagnostics, Distribution
Rubicon Genomics, ThruPLEX, PicoPLEX

Batu Biologics Announces FDA Development Plans for ValloVax(TM) Angiogenesis-Targeting Cancer Vaccine

Mon, 06/09/2014 - 11:47
Company Plans to Develop “Next Generation” Govallo Cancer Vaccine, VG-1000, for American Population DIEGO--(Healthcare Sales & Marketing Network)--Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax™, a can...
Biopharmaceuticals, Oncology
Batu Biologics, Govallo Cancer Vaccine, ValloVax, VG-1000

FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Leigh Syndrome

Mon, 06/09/2014 - 11:31
EPI-743 in phase 2B development for Leigh syndrome MOUNTAIN VIEW, Calif., June 9, 2014 -- (Healthcare Sales & Marketing Network) -- Edison Pharmaceuticals today announced that the FDA has granted Orphan Drug status to vatiquinone for the treatment of L...
Edison Pharmaceuticals, vatiquinone, Leigh syndrome

Cheetah Medical Secures $5 Million Investment from HighCape Partners

Fri, 06/06/2014 - 12:56
Extends February 2014 Financing with Addition of New Strategic Investor NEWTON, Mass., June 6, 2014 -- (Healthcare Sales & Marketing Network) -- Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, today announced that it has...
Devices, Monitoring, Venture Capital
Cheetah Medical, CHEETAH NICOM, non-invasive hemodynamic monitoring

Lombard Medical Aorfix(TM) Highlighted at 2014 Society for Vascular Surgery Annual Meeting

Fri, 06/06/2014 - 12:49
Only On-Label Stent Graft Approved for Highly Angulated AAA Cases IRVINE, Calif. & LONDON--(Healthcare Sales & Marketing Network)--Lombard Medical, Inc. (EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic an...
Devices, Interventional
Lombard Medical, Endovascular Aortic Repair, AAA, Aorfix, Stent Graft

Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President

Fri, 06/06/2014 - 12:43
NEW YORK and HERZLIYA-PITUACH, Israel, June 6, 2014 -- (Healthcare Sales & Marketing Network) -- Immune Pharmaceuticals Inc. (IMNP.ST) (IMNP.ST) ("Immune" or "the Company") appointed Mr. Gad Berdugo as new independent director and Karin...
Biopharmaceuticals, Personnel
Immune Pharmaceuticals

Senseonics Raises $20 Million

Thu, 06/05/2014 - 15:57
GERMANTOWN, MD--(Healthcare Sales & Marketing Network) - Senseonics, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, announced th...
Devices, Monitoring, Endocrinology, Personnel
Senseonics, glucose monitoring

Dehaier Receives CFDA Approval for Morpheus Ox Sleep Diagnostic Software

Thu, 06/05/2014 - 15:52
BEIJING, June 5, 2014 -- (Healthcare Sales & Marketing Network) -- Dehaier Medical Systems Ltd. (DHRM) ("Dehaier" or the "Company"), an emerging leader in development, assembly, marketing and sale of medical devices and sleep respirator...
Devices, Regulatory
Dehaier Medical Systems, Morpheus Ox

Cook Medical Makes Zilver(R) PTX(R) Drug-Eluting Stent Available in Canada

Thu, 06/05/2014 - 15:48
BLOOMINGTON, Ind.--(Healthcare Sales & Marketing Network)--Cook Medical launched its Zilver® PTX® Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It’s the first drug-c...
Devices, Interventional
Cook Medical, Zilver PTX, drug eluting stent, peripheral stent

QT Vascular Announces FDA Clearance of Chocolate PTCA Balloon Catheter

Thu, 06/05/2014 - 15:43
Chocolate® PTCA FDA clearance opens large new market opportunity SINGAPORE, June 5, 2014 -- (Healthcare Sales & Marketing Network) -- QT Vascular Ltd. (QT Vascular) is pleased to announce that on 4 June 2014, its wholly owned US subsidiary, TriReme...
Devices, Interventional Cardiology, FDA
QT Vascular, TriReme Medical, Chocolate PTCA, Balloon Catheter

ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine

Thu, 06/05/2014 - 13:04
SOLO I Trial studied single-dose ORBACTIVTM (oritavancin) in the treatment of acute bacterial skin and skin structure infections caused by Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) PARSIPPANY, N.J.--(Healthcar...
The Medicines Company, ORBACTIV, oritavancin, MRSA, ABSSSI

Trevi Therapeutics Announces $25 Million Series B Financing Led by TPG Biotech for Development of Nalbuphine ER

Wed, 06/04/2014 - 14:01
Company Initiating Activities for Pivotal Trials in Chronic Pruritic Conditions of Uremic Pruritus and Prurigo Nodularis NEW HAVEN, Conn.--(Healthcare Sales & Marketing Network)--Trevi Therapeutics, Inc. (“Trevi” or the “Company”), a clinical stage biot...
Biopharmaceuticals, Venture Capital
Trevi Therapeutics, Nalbuphine ER, pruritus

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong